AI Article Synopsis
- The study explores reboot surgery as an additional treatment option for EGPA patients experiencing persistent nasal issues despite receiving monoclonal antibody therapy (Mepolizumab) and multiple prior surgeries.* -
- Clinical data and evaluations, including symptom severity scores and nasal endoscopy, were collected before and after the reboot surgery on two patients suffering from severe sinonasal disease.* -
- Post-surgery results indicated significant improvement in nasal symptoms, with no nasal polyps detected during endoscopy and a reduction in eosinophils in biopsy samples, suggesting reboot surgery may be beneficial for similar patients.*
Article Abstract
Purpose: In the era of precision medicine, target-therapy with monoclonal antibodies (mAb) has enabled new treatment options in patients affected by eosinophilic granulomatosis with polyangiitis (EGPA). Nevertheless, sometimes unsatisfactory results at a nasal level may be observed. The aim of this study is to describe reboot surgery as a potential adjuvant strategy in multi-operated, yet uncontrolled EGPA patients treated with Mepolizumab.
Methods: We performed reboot surgery on EGPA patients with refractory CRSwNP. We obtained clinical data, nasal endoscopy, nasal biopsy, and symptom severity scores two months before surgery and 12 months after it. Computed tomography (CT) prior to surgery was also obtained.
Results: Two patients were included in the study. Baseline sinonasal disease was severe. Systemic EGPA manifestations were under control, and the patients received previous mepolizumab treatment and previous surgery with no permanent benefits on sinonasal symptoms. Twelve months after surgery, nasal symptoms were markedly improved; endoscopy showed an absence of nasal polyps and there were fewer eosinophils at histology.
Conclusions: We presented the first experience of two EGPA patients with refractory CRSwNP who underwent non-mucosa sparing (reboot) sinus surgery; our results support the possible adjuvant role of reboot surgery in this particular subset of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143226 | PMC |
| http://dx.doi.org/10.3390/jpm13040647 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral creatine-modified selenium-based hyaluronic acid nanogel mediated mitochondrial energy recovery to drive the treatment of inflammatory bowel disease.
J Nanobiotechnology
November 2024
Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, 200092, P. R. China.
Article Synopsis
- Mitochondrial dysfunction plays a significant role in inflammatory bowel disease (IBD), yet there are limited reports on targeted treatments that address this issue.
- Researchers developed a novel oral treatment called HA-Cr nanogel, which combines selenium and creatine to enhance mitochondrial energy metabolism and eliminate reactive oxygen species (ROS) specifically at inflammation sites.
- The HA-Cr nanogel showed promising results in improving IBD symptoms by restoring mitochondrial function, reducing inflammatory macrophage activity, repairing gut mucosa, and supporting microbial health, suggesting a new avenue for IBD treatment.
Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone.
Fertil Steril
October 2024
Division of Male Reproductive Medicine and Surgery, Scott Department of Urology, Baylor College of Medicine, Houston, Texas. Electronic address:
Objective: To study improvements in spermatogenesis in men with a history of testosterone therapy using a novel fertility treatment regimen.
Design: A single-center retrospective cohort analysis.
Setting: Clinic.
Rebooting the Adaptive Immune Response in Immunotherapy-Resistant Lung Adenocarcinoma Using a Supramolecular Albumin.
Small
December 2024
Department of Medical Oncology and Department of Talent Highland, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, P. R. China.
Despite the availability of immune checkpoint inhibitors (ICBs) significantly prolonging the life expectancy of some lung adenocarcinoma (LUAD) patients, their implementation and long-term effectiveness are hampered by the growing issue of acquired resistance. Herein, the bioinformatics analysis of immunotherapy-resistant LUAD patients and the system analysis of Anti-PD1-resistant mice models once again validate that the resistance-associated Wnt/β-catenin pathway offers a promising avenue for ICB sensitization. Consequently, a mild and convenient self-assembly between albumin and carnosic acid (CA), a Wnt inhibitor is employed, to develop a supramolecular albumin known as ABCA, serving as a reactivator for ICB.
View Article and Find Full Text PDFNon-Mucosa Sparing (Reboot) Surgery as a Possible Rescue Therapy in Patients Locally Unresponsive to Biologics.
Ear Nose Throat J
September 2024
Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Rozzano - Milan, Italy.
Evaluation of effectiveness of non-mucosa-sparing (eg, reboot) surgery in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), poorly responders to mAb therapy, who failed repeated comprehensive endoscopic surgeries. Retrospective observational study. Patients who were under mAb for a comorbid condition but still had no control over their CRSwNP were included.
View Article and Find Full Text PDFBailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
Lancet Neurol
August 2024
Interventional Neuroradiology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address:
Article Synopsis
- - The study investigated the potential benefits of bailout angioplasty or stenting (BAOS) for patients with large vessel occlusion acute ischemic stroke (LVO-AIS) who experienced unsuccessful recanalization after thrombectomy, as poor outcomes are common in such cases.
- - This randomized controlled trial involved 348 participants from 36 hospitals across China, who were either assigned to the BAOS intervention group or a control group receiving standard therapy, with outcomes measured by changes in the modified Rankin Scale at 90 days.
- - Findings indicated a diverse participant demographic, primarily male, with a median age of 63, and both safety and efficacy of the BAOS procedure were evaluated without loss to follow-up for the primary outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!